in the UK. A small, open-label study of MTX demonstrated analgesic efficacy equivalent to that of an NSAID, so this effect is also under study in a randomized trial. Trials targeting IL-1 with a number of mAb inhibitors have been disappointing in terms of symptom control. Several recent studies have investigated the effects of anti-TNF therapies in OA, with variable results. Studies of erosive hand OA have resulted in reduced swollen joint counts and reduced structural deterioration in joints with baseline clinical synovitis, but generally there have been no sustained analgesic benefits, though often anti-TNF therapy was given for short duration. Fewer studies have been conducted in knee OA, although a small number open-label study suggested good analgesic response. Through rational use of DMARDs we may determine the key inflammatory drivers of both pain and structural progression in OA. PsA has multiple, diverse clinical and radiographic presentations. This diversity interferes with the development of simple treatment algorithms and, historically, there has been little work done on early aggressive treatment and the effect of traditional DMARDs on characteristic features of the disease such as enthesitis and dactylitis. Evidence favouring MTX, the most commonly used drug in PsA, is mostly observational. The design of clinical trials has been hampered by the lack of appropriate outcome measures, now being corrected by organizations such as GRAPPA. In the last few years data are now emerging on the outcomes of early intervention and new drugs, and new targets, are becoming available. These issues will be reviewed in this presentation. Disclosure statement: P.H. has received honoraria from AbbVie, Celgene, Janssen, Novartis, Pfizer, BMS, Merck and UCB. Dermatologists and rheumatologists share the management of patients with a broad spectrum of clinical conditions that affect both the musculoskeletal system and the skin. Psoriasis and PsA is probably our most common link. We have witnessed the graduation from the gold treatment era, messy topical treatments such as tar and dithranol, diminishing availability of inpatient beds to the evolution of sophisticated patient targeted treatments. Intractable psoriasis and mutilating arthropathy are fortunately now a fairly rare occurrence. However there are new challenges such as paradoxical cutaneous side effects and a reduced immune surveillance that may allow skin cancers to thrive. How best can the two specialities interact to provide a patient centred system of care which is also efficient and economic? It is important that rheumatologists and dermatologists appreciate their similarities in approach to disease management but also our unique methods of assessment and treatment of complex disease such as psoriasis/PsA and cutaneous lupus. A variety of clinical examples of rheumatic skin disorders seen over a number of years will serve to illustrate points of diagnosis and treatment. Disclosure statement: L.B. has served on advisory boards for AbbVie, Pfizer and Janssen-Cilag.
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